New Gram-positive antibiotics: Better than vancomycin?

Current Opinion in Infectious Diseases

Volumn 24, Issue 6, 2011, Pages 515-520

  Van Hal, Sebastiaan J ^a,b   Paterson, David L ^b  

^a South Western Sydney Local Health Network   (Australia)

^b UNIVERSITY OF WESTERN SYDNEY   (Australia)

Author keywords

Antibiotic therapy; Gram positive; Methicillin resistant Staphylococcus aureus; Multidrug resistant

Indexed keywords

AZTREONAM; CEFTAROLINE; CEFTOBIPROLE; COTRIMOXAZOLE; DALBAVANCIN; DAPTOMYCIN; ICLAPRIM; LINEZOLID; RIFAMPICIN; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL INFECTION; BACTERIAL ENDOCARDITIS; COMMUNITY ACQUIRED PNEUMONIA; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; FEVER; FOOD AND DRUG ADMINISTRATION; HEADACHE; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; HYPERBILIRUBINEMIA; INFECTION COMPLICATION; LOADING DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NAUSEA AND VOMITING; NEPHROTOXICITY; OSTEOMYELITIS; PAIN; PROSPECTIVE STUDY; PROSTHETIC VALVE ENDOCARDITIS; QT PROLONGATION; REVIEW; SIDE EFFECT; SOFT TISSUE INFECTION; STREPTOCOCCUS INFECTION; THROMBOCYTOPENIA; UNITED STATES;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; GRAM-POSITIVE BACTERIA; HUMANS; PNEUMONIA; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 80055014041     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32834ab1de     Document Type: Review

References (49)

1. David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev 2010; 23:616-687.
2. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18-e55.
3. Haque NZ, Zuniga LC, Peyrani P, et al. Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-careassociated pneumonia. Chest 2010; 138:1356-1362.
4. Howden BP, Davies JK, Johnson PD, et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010; 23:99-139.
5. Wong-Beringer A, Joo J, Tse E, Beringer P. Vancomycin-associated nephrotoxicity: A critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents 2011; 37:95-101.
6. van Hal SJ, Paterson DL. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother 2011; 55:405-410.
7. Mendes RE, Moet GJ, Janechek MJ, Jones RN. In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates. Antimicrob Agents Chemother 2010; 54:2704-2706.
8. Mendes RE, Sader HS, Jones RN. Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe. Int J Antimicrob Agents 2010; 36:374-379.
9. Pfaller MA, Mendes RE, Sader HS, Jones RN. Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia. J Antimicrob Chemother 2010; 65:2396-2404.
10. Pfaller MA, Rhomberg PR, Sader HS, et al. Telavancin activity against Grampositive bacteria isolated from patients with skin and skin-structure infections. J Chemother 2010; 22:304-311.
11. Papaparaskevas J, Tzouvelekis LS, Tsakris A, et al. In vitro activity of tigecycline against 2423 clinical isolates and comparison of the available interpretation breakpoints. Diagn Microbiol Infect Dis 2010; 66:187-194.
12. Saravolatz LD, Pawlak J, Johnson LB. In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CAMRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-nonsusceptible S. aureus (DNSSA). Int J Antimicrob Agents 2010; 36:69-72.
13. Jung YJ, Koh Y, Hong SB, et al. Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. Crit Care Med 2010; 38:175-180.
14. Forrest GN, Tamura K. Rifampin combination therapy for nonmycobacterial infections. Clin Microbiol Rev 2010; 23:14-34.
15. Schirmer PL, Deresinski SC. Ceftobiprole: A new cephalosporin for the treatment of skin and skin structure infections. Expert Rev Anti Infect Ther 2009; 7:777-791.
16. File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010; 51:1395-1405.
17. Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010; 51:641-650.
18. Corey GR, Wilcox MH, Talbot GH, et al. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65 (SUPPL. 4):iv41-iv51.
19. Corrado ML. Integrated safety summary of CANVAS 1 and 2 trials: phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65 (SUPPL. 4):iv67-iv71.
20. Wilcox MH, Corey GR, Talbot GH, et al. CANVAS 2: the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65 (SUPPL. 4):iv53-iv65.
21. Zhanel GG, Calic D, Schweizer F, et al. New lipoglycopeptides: A comparative review of dalbavancin, oritavancin and telavancin. Drugs 2010; 70:859-886.
22. Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother 2009; 53:4069-4079.
23. Brink AJ, Richards GA, Cummins RR, Lambson J. Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalized patients treated for sepsis. Int J Antimicrob Agents 2008; 32:455-458.
24. Rubinstein E, Lalani T, Corey GR, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens. Clin Infect Dis 2011; 52:31-40.
25. Conte JE Jr, Golden JA, Kipps J, Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002; 46:1475-1480. (Pubitemid 34415331)
26. Kollef MH, Rello J, Cammarata SK, et al. Clinical cure and survival in Grampositive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004; 30:388-394. (Pubitemid 38375611)
27. Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124:1789-1797. (Pubitemid 37433574)
28. Beibei L, Yun C, Mengli C, et al. Linezolid versus vancomycin for the treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Int J Antimicrob Agents 2010; 35:3-12.
29. Kalil AC, Murthy MH, Hermsen ED, et al. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: A systematic review and meta-analysis. Crit Care Med 2010; 38:1802-1808.
30. Kunkel M, Chastre JE, Kollef M, et al. Linezolid vs vancomycin in the treatment of nosocomial pneumonia proven due to methicillin-resistant Staphylococcus aureus [abstract]. In: 48th Annual Meeting of the Infectious Diseases Soceity of America (IDSA); 2010 Boston: MA. 2010. Abstract 570.
31. Itani KM, Dryden MS, Bhattacharyya H, et al. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am J Surg 2010; 199:804-816.
32. Caffrey AR, Quilliam BJ, LaPlante KL. Comparative effectiveness of linezolid and vancomycin among a national cohort of patients infected with methicillinresistant Staphylococcus aureus. Antimicrob Agents Chemother 2010; 54:4394-4400.
33. Bounthavong M, Hsu DI. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): A meta-analysis. Curr Med Res Opin 2010; 26:407-421.
34. Sanchez Garcia M, De la Torre MA, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010; 303:2260-2264.
35. Morales G, Picazo JJ, Baos E, et al. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis 2010; 50:821-825.
36. Bliziotis IA, Plessa E, Peppas G, Falagas ME. Daptomycin versus other antimicrobial agents for the treatment of skin and soft tissue infections: A meta-analysis. Ann Pharmacother 2010; 44:97-106.
37. van Hal SJ, Paterson DL, Gosbell IB. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in daptomycin-naive patient: A review of the literature. Eur J Clin Microbiol Infect Dis 2011; 30:603-610.
38. Cui L, Isii T, Fukuda M, et al. An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus. Antimicrob Agents Chemother 2010; 54:5222-5233.
39. Crompton JA, North DS, Yoon M, et al. Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs. J Antimicrob Chemother 2010; 65:1784-1791.
40. Bassetti M, Nicco E, Ginocchio F, et al. High-dose daptomycin in documented Staphylococcus aureus infections. Int J Antimicrob Agents 2010; 36:459-461.
41. Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 2010; 50:1568-1574.
42. Chaftari AM, Hachem R, Mulanovich V, et al. Efficacy and safety of daptomycin in the treatment of Gram-positive catheter-related bloodstream infections in cancer patients. Int J Antimicrob Agents 2010; 36:182-186.
43. Miller BA, Gray A, Leblanc TW, et al. Acute eosinophilic pneumonia secondary to daptomycin: A report of three cases. Clin Infect Dis 2010; 50:e63-e68.
44. Lal Y, Assimacopoulos AP. Two cases of daptomycin-induced eosinophilic pneumonia and chronic pneumonitis. Clin Infect Dis 2010; 50:737-740.
45. FDA Drug Safety Communication. Eosinophilic pneumonia associated with the use of Cubicin (daptomycin); 2010 http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm220273.htm [Accessed April 2011].
46. Cai Y, Wang R, Liang B, et al. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 2011; 55:1162-1172.
47. FDA Drug Safety Communication. Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections; 2010. http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm [Accessed April 2011].
48. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992; 117:390-398.
49. Goldberg E, Paul M, Talker O, et al. Co-trimoxazole versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteraemia: A retrospective cohort study. J Antimicrob Chemother 2010; 65:1779-1783.